| 02/03 | Wells Fargo Adjusts Eli Lilly's Price Target to $360 From $375, Maintains Equal Weight .. | MT |
| 02/03 | Wells Fargo Adjusts Merck & Company Price Target to $120 From $125, Maintains Overweigh.. | MT |
| 02/03 | European Equities Move Modestly Higher Friday, But Poised to End Week Lower | MT |
| 02/03 | Truist Securities Adjusts Price Target on Merck & Company to $118 From $106, Maintains .. | MT |
| 02/03 | Morgan Stanley Adjusts Price Target on Eli Lilly to $455 From $440, Maintains Overweigh.. | MT |
| 02/03 | Morgan Stanley Adjusts Price Target on Merck & Company to $99 From $100, Maintains Equa.. | MT |
| 02/03 | ROCHE HOLDINGS AG : Credit Suisse maintains a Buy rating | MD |
| 02/03 | AlphaValue/Baader Europe Lowers Price Target on Roche, Upgrades Recommendation to Buy F.. | MT |
| 02/03 | SVB Securities Adjusts Merck & Company's Price Target to $122 From $120, Maintains Outp.. | MT |
| 02/03 | Merck Says Trial of Keytruda and Chemotherapy to Treat Endometrial Cancer Meets Primary.. | MT |
| 02/03 | Merck's Keytruda Meets Main Endpoints in Endometrial Carcinoma Study | DJ |
| 02/03 | Merck Announces Phase 3 NRG-GY018 Trial Evaluating Keytrudav | CI |
| 02/03 | ROCHE HOLDINGS AG : Deutsche Bank keeps a Sell rating | MD |
| 02/02 | Merck & Co. Flags Lower COVID-19 Drug Sales in FY23 | MT |
| 02/02 | Prospects of Fed's Rate-Hiking Cycle Ending Soon Lifts Equities | MT |
| 02/02 | Sector Update: Healthcare Stocks Stage Thursday Retreat | MT |
| 02/02 | Sector Update: Health Care Falls as Investors Chase Growth Sectors | MT |
| 02/02 | Sector Update: Health Care | MT |
| 02/02 | Global markets live: ABB, Infineon, Shell, Metlife, Boeing... | |
| 02/02 | Eli Lilly Down Over 6%, on Pace for Largest Percent Decrease Since March 2021 -- Data T.. | DJ |
| 02/02 | European Equities Move Lower Following ECB Rate Hike | MT |
| 02/02 | Trending : Roche Guides for 2023 Sales, Earnings Decline on Covid-19 Drop | DJ |
| 02/02 | Merck Posts Mixed Fourth-Quarter Results, Issues Downbeat Full-Year Earnings Outlook | MT |
| 02/02 | Transcript : Eli Lilly and Company, Q4 2022 Earnings Call, Feb 02, 2023 | CI |
| 02/02 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
| 02/02 | Eli Lilly Fourth-Quarter Results Decline on Foreign-Exchange Headwinds; Full-Year Earni.. | MT |
| 02/02 | Transcript : Roche Holding AG, 2022 Earnings Call, Feb 02, 2023 | CI |
| 02/02 | Transcript : Merck & Co., Inc., Q4 2022 Earnings Call, Feb 02, 2023 | CI |
| 02/02 | Eli Lilly Reports 12% Net Income Growth in FY22; Lifts FY23 EPS Guidance | MT |
| 02/02 | Eli Lilly Q4 Non-GAAP Earnings, Revenue Decrease; Raises 2023 Adjusted Earnings Outlook | MT |
| 02/02 | ROCHE HOLDINGS AG : Jefferies gives a Neutral rating | MD |
| 02/02 | Merck Q4 Adjusted Earnings Slip, Sales Increase; Issues 2023 Outlook | MT |
| 02/02 | NOVO NORDISK : Credit Suisse remains Neutral | MD |
| 02/02 | GUIDANCE: (LLY) ELI LILLY AND COMPANY Expects Fiscal Year 2023 EPS Range $8.35 .. | MT |
| 02/02 | Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q4 Revenue $7.30B, vs. Street Est of.. | MT |
| 02/02 | Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q4 EPS $2.09, vs. Street Est of $1.8.. | MT |
| 02/02 | Eli Lilly and Company Revises Earnings Guidance for the Year 2023 | CI |
| 02/02 | Merck & Co., Inc. Provides Earnings Guidance for the Year 2023 | CI |
| 02/02 | GUIDANCE: (MRK) MERCK & CO. Expects Fiscal Year 2023 Revenue Range $57.2B - $58.. | MT |
| 02/02 | GUIDANCE: (MRK) MERCK & CO. Expects Fiscal Year 2023 EPS Range $6.80 - $6.95 | MT |
| 02/02 | Earnings Flash (MRK) MERCK & CO. Reports Q4 Revenue $13.83B | MT |
| 02/02 | Earnings Flash (MRK) MERCK & CO. Posts Q4 EPS $1.62 | MT |
| 02/02 | NOVO NORDISK : Deutsche Bank gives a Buy rating | MD |
| 02/02 | ROCHE HOLDINGS AG : Goldman Sachs reaffirms its Buy rating | MD |
| 02/02 | ROCHE HOLDINGS AG : JP Morgan remains a Sell rating | MD |
| 02/02 | Roche Names CEO for Pharmaceuticals Unit | MT |
| 02/02 | Roche Braces for Lower Sales in 2023 as Demand for COVID-19 Products Dwindle | MT |
| 02/02 | Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products -- Update | DJ |
| 02/02 | Roche flags 2023 earnings decline on slump in COVID products | RE |
| 02/02 | Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products | DJ |
| 02/02 | Roche's FY22 Profit Falls as COVID-19 Boost Fades | MT |
| 02/02 | Roche Holding AG Announces Executive Appointments | CI |
| 02/02 | Roche Holding AG Provides Group Sales Guidance for the Year 2023 | CI |
| 02/02 | Roche Proposes Dividend for 2023 | CI |
| 02/02 | Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit | MT |
| 02/01 | Merck & Co. Says No Direct Evidence of COVID-19 Pill Leading to New Variants | MT |
| 02/01 | Global markets live: AMD, Amgen, Electronic Arts, PayPal, Snap... | |
| 02/01 | Trending: Novartis's 4Q Net Profit Declines on Poor Drug Performances | DJ |
| 02/01 | Novo Nordisk Q4 Earnings, Sales Rise; Issues 2023 Outlook; to Start 28 Billion Kroner S.. | MT |
| 02/01 | Novo Nordisk A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 202.. | CI |
| 02/01 | Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DK.. | CI |
| 02/01 | Novo Nordisk A/S Provides Earnings Guidance for the Year 2023 | CI |
| 02/01 | Tranche Update on Novo Nordisk A/S (CPSE:NOVO B)'s .. | CI |
| 02/01 | Novo Nordisk A/S Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 02/01 | NOVO NORDISK : Jefferies gives a Sell rating | MD |
| 02/01 | Transcript : Novo Nordisk A/S, 2022 Earnings Call, Feb 01, 2023 | CI |
| 02/01 | NOVO NORDISK : Sell rating from UBS | MD |
| 02/01 | NOVO NORDISK : JP Morgan maintains a Buy rating | MD |
| 02/01 | Scancell Holdings Names Jean-Michel Cossery Nonexecutive Chairman | DJ |
| 02/01 | European shares gain on pharma boost; Fed policy decision on tap | RE |
| 02/01 | Novo Nordisk Launches $4 Billion Buyback as 4Q Earnings Beat Forecasts | DJ |
| 02/01 | Novo Nordisk to Launch New DKK28 Billion Share Repurchase Program | MT |
| 02/01 | Novo Nordisk Reports 16% Jump in FY22 Net Profit on Double-Digit Sales Growth | MT |
| 02/01 | Novartis Lifts Dividend Despite 4Q Sales, Profit Decline | DJ |
| 02/01 | Novo Nordisk A/S Proposes Final Dividend for 2022 | CI |
| 02/01 | European Commission Expands Marketing Permit for Roche's Hemlibra | MT |
| 02/01 | European Commission Approves the Expansion of Roche's Hemlibra European Union Marketing.. | CI |
| 02/01 | Novo Nordisk A/S authorizes a Buyback Plan. | CI |
| 01/31 | Amgen revenue falls slightly as Lilly COVID deal contributes less | RE |
| 01/31 | Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development | MT |
| 01/31 | UBS Adjusts Eli Lilly and Company Price Target to $406 From $420, Maintains Buy Rating | MT |
| 01/31 | UBS Adjusts Merck & Company Price Target to $108 From $105, Maintains Neutral Rating | MT |
| 01/31 | Idorsia Files European Marketing Authorization Application For Resistant Hypertension T.. | MT |
| 01/31 | PrescriberPoint, Inc. announced that it has received funding from Eli Lilly and Company.. | CI |
| 01/31 | Carsgen Therapeutics Holdings Limited Announces Collaboration Agreement with F. Hoffman.. | CI |
| 01/30 | Roche's Diagnostics Division Joins Jana Care on Remote Blood Testing Platform | MT |
| 01/30 | Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close | MT |
| 01/30 | Sector Update: Health Care | MT |
| 01/30 | Johnson & Johnson Worst Performer in the DJIA So Far Today -- Data Talk | DJ |
| 01/30 | Top Midday Decliners | MT |
| 01/30 | Jana Care, Inc. to Enter Collaboration with Roche Diagnostics to Develop and Distribute.. | CI |
| 01/30 | Mega-Cap Tech Earnings on Tap; Fed's Policy Leanings Cool US Equity Investors' Risk App.. | MT |
| 01/30 | AstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun.. | MT |
| 01/30 | Johnson & Johnson's Bankruptcy Petition for Talc Unit Dismissed by Court; Shares Down M.. | MT |
| 01/30 | Johnson & Johnson Stock Falls Amid Reports US Appeals Court Rejected Company's Use of B.. | MT |
| 01/30 | Johnson & Johnson Talc Bankruptcy Case Thrown Out b.. | MT |
| 01/30 | Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment | AN |
| 01/30 | European Equities Start the Week Modestly Higher Amid German GDP Contraction | MT |
| 01/30 | Berenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra.. | MT |
| 01/30 | Berenberg Lowers Price Target on Roche, Maintains Buy Recommendation | MT |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
